Literature DB >> 33664732

The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.

Yang Li1, Gen Li1, Jian Zhang1, Xiaoli Wu2, Xi Chen3.   

Abstract

γδ T cells are the unique T cell subgroup with their T cell receptors composed of γ chain and δ chain. Unlike αβ T cells, γδ T cells are non-MHC-restricted in recognizing tumor antigens, and therefore defined as innate immune cells. Activated γδ T cells can promote the anti-tumor function of adaptive immune cells. They are considered as a bridge between adaptive immunity and innate immunity. However, several other studies have shown that γδ T cells can also promote tumor progression by inhibiting anti-tumor response. Therefore, γδ T cells may have both anti-tumor and tumor-promoting effects. In order to clarify this contradiction, in this review, we summarized the functions of the main subsets of human γδ T cells in how they exhibit their respective anti-tumor or pro-tumor effects in cancer. Then, we reviewed recent γδ T cell-based anti-tumor immunotherapy. Finally, we summarized the existing problems and prospect of this immunotherapy.
Copyright © 2021 Li, Li, Zhang, Wu and Chen.

Entities:  

Keywords:  human; immunity; immunotherapy; tumor; γδ T cells

Mesh:

Substances:

Year:  2021        PMID: 33664732      PMCID: PMC7921733          DOI: 10.3389/fimmu.2020.619954

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  200 in total

Review 1.  The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity.

Authors:  Guranda Chitadze; Hans-Heinrich Oberg; Daniela Wesch; Dieter Kabelitz
Journal:  Trends Immunol       Date:  2017-07-11       Impact factor: 16.687

2.  Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on Vγ9Vδ2 T cell activation.

Authors:  Siyi Gu; Joseph R Sachleben; Christopher T Boughter; Wioletta I Nawrocka; Marta T Borowska; Jeffrey T Tarrasch; Georgios Skiniotis; Benoît Roux; Erin J Adams
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-14       Impact factor: 11.205

3.  Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.

Authors:  Joshua M Lang; Mahazarin R Kaikobad; Marianne Wallace; Mary Jane Staab; Dorothea L Horvath; George Wilding; Glenn Liu; Jens C Eickhoff; Douglas G McNeel; Miroslav Malkovsky
Journal:  Cancer Immunol Immunother       Date:  2011-06-07       Impact factor: 6.968

Review 4.  gammadelta T cells link innate and adaptive immune responses.

Authors:  Wolfgang Holtmeier; Dieter Kabelitz
Journal:  Chem Immunol Allergy       Date:  2005

5.  Distinct subpopulations of gamma delta T cells are present in normal and tumor-bearing human liver.

Authors:  Tony Kenna; Lucy Golden-Mason; Suzanne Norris; John E Hegarty; Cliona O'Farrelly; Derek G Doherty
Journal:  Clin Immunol       Date:  2004-10       Impact factor: 3.969

6.  Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.

Authors:  Yu Abe; Masato Muto; Mie Nieda; Yasunori Nakagawa; Andrew Nicol; Touru Kaneko; Shigenori Goto; Kiyoshi Yokokawa; Kenshi Suzuki
Journal:  Exp Hematol       Date:  2009-05-04       Impact factor: 3.084

7.  Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.

Authors:  Jaafar Bennouna; Emmanuelle Bompas; Eve Marie Neidhardt; Frédéric Rolland; Irène Philip; Céline Galéa; Samuel Salot; Soraya Saiagh; Marie Audrain; Marie Rimbert; Sylvie Lafaye-de Micheaux; Jérôme Tiollier; Sylvie Négrier
Journal:  Cancer Immunol Immunother       Date:  2008-02-27       Impact factor: 6.968

8.  Human peripheral gammadelta T cells possess regulatory potential.

Authors:  Anja A Kühl; Nina N Pawlowski; Katja Grollich; Maike Blessenohl; Jürgen Westermann; Martin Zeitz; Christoph Loddenkemper; Jörg C Hoffmann
Journal:  Immunology       Date:  2009-09-11       Impact factor: 7.397

9.  Pediatric Primitive Neuroectodermal Tumors of the Central Nervous System Differentially Express Granzyme Inhibitors.

Authors:  Jeroen F Vermeulen; Wim van Hecke; Wim G M Spliet; José Villacorta Hidalgo; Paul Fisch; Roel Broekhuizen; Niels Bovenschen
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

10.  GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.

Authors:  Trudy Straetemans; Guido J J Kierkels; Ruud Doorn; Koen Jansen; Sabine Heijhuurs; Joao M Dos Santos; Anna D D van Muyden; Henri Vie; Béatrice Clemenceau; Reinier Raymakers; Moniek de Witte; Zsolt Sebestyén; Jürgen Kuball
Journal:  Front Immunol       Date:  2018-05-30       Impact factor: 7.561

View more
  15 in total

1.  Identification of immunophenotypes in esophageal squamous cell carcinoma based on immune gene sets.

Authors:  Danlei Song; Yongjian Wei; Yuping Hu; Yueting Sun; Min Liu; Qian Ren; Zenan Hu; Qinghong Guo; Yuping Wang; Yongning Zhou
Journal:  Clin Transl Oncol       Date:  2022-01-31       Impact factor: 3.405

2.  Resistance to Immunotherapy: Mechanisms and Means for Overcoming.

Authors:  Mohamad A Salkeni; John Y Shin; James L Gulley
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

4.  Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies.

Authors:  Navdeep Jhita; Sunil S Raikar
Journal:  Explor Immunol       Date:  2022-06-07

Review 5.  Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.

Authors:  José Saura-Esteller; Milon de Jong; Lisa A King; Erik Ensing; Benjamin Winograd; Tanja D de Gruijl; Paul W H I Parren; Hans J van der Vliet
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

Review 6.  Advances in NK cell production.

Authors:  Fang Fang; Siqi Xie; Minhua Chen; Yutong Li; Jingjing Yue; Jie Ma; Xun Shu; Yongge He; Weihua Xiao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-05       Impact factor: 22.096

7.  Identification of a Novel PPAR Signature for Predicting Prognosis, Immune Microenvironment, and Chemotherapy Response in Bladder Cancer.

Authors:  Ke Zhu; Wen Deng; Hui Deng; Xiaoqiang Liu; Gongxian Wang; Bin Fu
Journal:  PPAR Res       Date:  2021-12-30       Impact factor: 4.964

Review 8.  γδ T Cells for Leukemia Immunotherapy: New and Expanding Trends.

Authors:  Mateus de Souza Barros; Nilberto Dias de Araújo; Fábio Magalhães-Gama; Thaís Lohana Pereira Ribeiro; Fabíola Silva Alves Hanna; Andréa Monteiro Tarragô; Adriana Malheiro; Allyson Guimarães Costa
Journal:  Front Immunol       Date:  2021-09-22       Impact factor: 7.561

9.  High TRGV 9 Subfamily Expression Marks an Improved Overall Survival in Patients With Acute Myeloid Leukemia.

Authors:  Xueting Kong; Jiamian Zheng; Xiaxin Liu; Wandi Wang; Xuan Jiang; Jie Chen; Jing Lai; Zhenyi Jin; Xiuli Wu
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

Review 10.  Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.

Authors:  Cai Zhang; Yuan Hu; Weihua Xiao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2021-07-15       Impact factor: 22.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.